Teva`s Generic Dasatinib Receives Approval in the U.S.
Teva Pharma Generic Dasatinib Receives Tentative Approval in US
Accord Healthcare Dasatinib Receives Approval in Europe
Alembic Pharma's Generic Dasatinib Receives Approval in the U.S.
Bristol-Myers Squibb Co. filed a lawsuit alleging XSpray Pharma AB’s proposed branded generic version of Sprycel tablets infringes two patents for the blockbuster leukemia drug, which generated more revenue last year than all but five of Bristol-Myers’ products.
Health Canada Issues Recall of Reddy-Dasatinib: out of specification
Researchers from the Institute of Cancer Research (ICR), London, UK, have identified a new combination of two approved cancer drugs that can be used to treat children suffering from incurable brain cancer.
Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that it has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric pH level. HyNap-Dasa is being developed both as a generic and improved version of the marketed drug Sprycel® (dasatinib).
Shilpa Medicare Limited has launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name 'DASASHIL'.
Dr Reddy's Laboratories on Monday said it has launched blood cancer drug Invista in the country. The company's product is a formulation of Dasatinib that is bioequivalent to the innovator brand, Dr Reddy's Laboratories said in a statement.